ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years Early Stage Breast Cancer
Status:
Recruiting
Trial end date:
2030-01-15
Target enrollment:
Participant gender:
Summary
Rationale and relevance for patients and the scientific community. In low risk early stage
patients ≥70 years, exclusive Partial Breast Irradiation (PBI) as radiation therapy (RT)
approach might be superior in terms of Health-Related Quality of Life (HRQoL), when compared
to exclusive endocrine therapy (ET) following breast-conserving surgery (BCS). Assuming an
equal rate of disease control, unnecessary long-term toxicity of ET may be avoided.